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Abstract Intrathecal baclofen delivery via implantable pump
represents an important modality for symptomatic relief in
patients with chronic spasticity. Pumps are routinely im-
planted subcutaneously in the anterior abdominal wall. We
describe two unusual cases where skin-related complications
necessitated revision surgery in order to relocate the pump to
alternative sites. The first patient was an international power
canoeist, whose strenuous exercise programme interfered with
his pump’s original siting. The second patient was a cachectic
university student with a history of cerebral palsy, who main-
tained low body mass despite attempted weight gain. The
relocation of these two intrathecal devices to the medial com-
partment of the right thigh and right iliac fossa, respectively, is
described.
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Introduction
Spasticity is regarded as a disorder of muscle tone secondary
to a hypersensitivity to the stretch reflex. It leads to excessive
muscle resistance to passive movement velocity, resulting in
hypertonia and is a characteristic feature of upper motor neu-
ron lesions such as cerebral palsy (CP) and hereditary spastic
diplegia (HSD). In these conditions, damage to descending
inhibitory neurons results in a failure to inhibit spinal motor
neuron pools [1]. Whilst spasticity is a defining feature of
congenital conditions such as CP and HSD, it can also be
acquired later in life with a prevalence of 28–38 % in stroke,
41–66 % in multiple sclerosis and 13 % in patients following
neurological trauma [2]. Managing spasticity is essential for
optimising patient pain, mobility and function.
Baclofen is a γ–aminobutyric acid (GABA) analogue that
binds to presynaptic GABAB (G protein-coupled) receptors in
the dorsal horn of the spinal cord. It inhibits neurotransmission
in the spinal cord, leading to muscle relaxation. Despite high
oral bioavailability, the anti-spasmodic efficacy of baclofen is
limited by systemic side effects, necessitating a targeted ap-
proach. This has led to the development of intrathecal baclo-
fen (ITB) delivery via implantable pumps which infuse bac-
lofen continuously into the subarachnoid space. Pioneering
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work by Penn and Kroin [3, 4] in the 1980s resulted in suc-
cessful use of ITB pumps to alleviate spasticity of spinal ori-
gin. The technique was widely adopted and achieved symp-
tomatic relief with minimal systemic side effects [5]. ITB also
had the added advantage of being reversible and programma-
ble to a wide range of dosing regimens. A recent systematic
review has confirmed a statistically significant decrease in
spasticity following intrathecal baclofen pump use [6] with a
typical complication rate of between zero and 2.24 complica-
tions per implant [7]. Unfortunately intrathecal therapy is cost-
ly with a recent study estimating the 5-year cost to be approx-
imately $49,000 relative to alternative therapy [8]. In the UK,
the National Commissioning Board has defined strict criteria
for the funding of intrathecal pumps [9].
Typically, ITB pumps are sited subcutaneously in the ante-
rior abdominal wall. In patients with relatively little subcuta-
neous adipose tissue (particularly in children [10]), ITB
pumps can be sited in the subfascial plane. This technique,
pioneered by Grabb and Pittman [11] in a paediatric cohort in
1998, provides greater stability for the device with lower ten-
sion placed on the overlying abdominal incision. As such, this
approach has reduced instances of implant-site skin dehis-
cence and has a favourable aesthetic appearance—particularly
in underweight patients. Despite these two widely practiced
methods, a minority of patients present with unique circum-
stances not amenable to either placement solution. In these
cases, there is limited experience of alternate placement sites
described in the literature. Herein, we report on two patients in
whom alternative sites for pump placement were sought, with
subsequent good clinical outcomes.
Case reports
Case 1
A 41-year-old man with a background of hereditary spastic
paraplegia was not tolerating the side effects of oral baclofen
and underwent ITB pump placement subcutaneously in the
right lower quadrant of the abdomen. He regularly competes
as an international power canoeist, and has a muscular build.
Ten months following ITB placement, he attended clinic
with a history of pump site discomfort. On examination, the
implanted pump had eroded a substantial amount of subcuta-
neous adipose tissue and the overlying skin was erythematous
and tender. C-reactive protein (CRP) and erythrocyte sedi-
mentation rate (ESR) were both within normal range. Whilst
the overlying skin was intact on presentation, computed to-
mography demonstrated a fluid collection posterior to the
pump. The fluid was aspirated with a needle, and was con-
firmed sterile on Gram stain microscopy and culture; this fluid
was sampled for microbiological analysis and determined to
be sterile. Twelve weeks later, the pump was re-sited to the
right medial thigh. Intraoperatively, the pumpwas disconnect-
ed and removed from the original site. There was no evidence
of infection in the pump cavity. A medial mid-thigh transverse
incision was made and a subcutaneous pouch was created,
into which the original pump was inserted. A new catheter
was connected to the pump. It was first tunnelled out through
an intermediate proximal thigh incision, in which the tubing
was anchored to the muscle fascia (Fig. 1). Subsequently, the
same catheter was tunnelled to the original abdominal pouch,
where it was connected to the original distal spinal catheter
with a straight connector. The pouch was irrigated with gen-
tamicin solution and closed in layers.
Eight months later, the patient presented to his general
practitioner complaining of swelling around the revised place-
ment site. For the next 6 months he described intermittent
episodes of warmth and erythema at the pump site that wors-
ened during his physical training regime. Towards the end of
this period we reviewed the patient in clinic and concluded
that this swelling was likely precipitated by exercise. Ten days
subsequent to this clinic visit, he was admitted due to in-
creased swelling, pain and ulceration at the pump site. CRP,
ESR and white blood cell count (WBC) were all normal. He
underwent further surgery: the lateral part of the wound was
reopened and thin, inflamed skin edges excised. The wound
was washed and closed. Microbiological assessment of the
excised skin edges revealed no evidence of infection.
At 1-month post-operative follow-up, evidence of dehis-
cence was still present along with underlying haematoma for-
mation. Thinning of skin and small discharging vesicles were
noted lateral to the scar. The patient underwent further surgery
under the plastic surgery and neurosurgery team. The wound
was debrided and washed out. A new proximal pocket was
developed superficial to the deep fascia anterior to the thigh
and the pumpwas re-sited for a second time. At post-operative
follow-up, the patient was well and the wound was well
healed. Six months later, there was no collection surrounding
Fig. 1 a Subcutaneous location of intrathecal baclofen pump device in
the right medial thigh 5 months after surgery. b Radiograph showing the
subcutaneous placement of the intrathecal baclofen pump device with
associated catheter located in the right medial thigh. The catheter is
seen passing superiorly from the device towards the right neck of femur
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the pump, the patient was receiving regular ITB pump refills
and is able to train without difficulty.
Case 2
A 30-year-old man with a background of cerebral palsy and
spastic diplegia had a right flank ITB pump inserted 7 years
previously. During a routine follow-up clinic, the ITB
pump was visibly protruding through the subcutaneous tis-
sue of the abdominal wall (Fig. 2). This complication oc-
curred following a period of significant weight loss after his
recent move to university. Otherwise, the patient was
apyrexial and there was no erythema, purulent discharge
or raised temperature in the skin. WBC and CRP were
normal.
Six days later, the patient underwent a re-siting proce-
dure. The old transverse wound was opened and the origi-
nal pump was dissected from its capsule. It was then
inserted into the potential space developed between the su-
perior rectus abdominus and the posterior rectus sheath.
The pump was anchored to the posterior rectus sheath with
polyester suture. A new proximal catheter was attached to
the pump and brought out superficial to the superficial linea
alba, where it was connected to the old distal catheter using
a straight connector (Fig. 3). The wound was closed in
layers.
The patient was monitored in the ITB pump clinic, where
he received regular refills. Twelve months later, the pump was
stable and the wound remained intact.
Discussion
Intrathecal baclofen delivery via an implanted pump is a safe,
effective and reversible treatment for spasticity, with minimal
systemic side effects. However, it requires a surgical proce-
dure of pump and catheter insertion and regular refilling of the
pump with baclofen. Therefore, it carries similar risks associ-
ated with all implanted foreign bodies. These include infec-
tion, both at the pump site and lumbar spinal region, skin
irritation and wound dehiscence in addition to pump failure,
catheter dysfunction and pump hypermobility.
We described two cases of an ITB pump eroding through the
abdominal wall, requiring re-siting procedures. Both patients
presented a surgical challenge in terms of finding an alternative
pump site adequate to their body habitus and unique lifestyles.
The first patient was an international power canoeist with a
muscular build and low body fat. Considering his regular par-
ticipation in strenuous exercise, a primary repair of the original
abdominal site would be prone to further erosion. We consid-
ered the possibility of an infraclavicular placement in both pa-
tients; however, it was thought that a site overlying the
pectoralis muscles would carry similar risks to the original ab-
dominal placement. In our first patient, we replaced the pump in
the unusual location of the right medial thigh (Fig. 1). Because
the patient was paraplegic, this site had much less overlying
skin movement and, thus, risk of erosion. In our second patient,
with relatively less regular strain placed on the abdominal re-
gion, a location tethered to the rectus sheath was more appro-
priate and aesthetically appealing (Fig. 3).
While the abdomen remains the most common site for ITB
pump insertion, as the present two cases demonstrated, occa-
sionally alternatives need to be sought, due to various unique
anatomical reasons. An ideal ITB pump implant site should be:
Fig. 2 a Dehiscence of scar overlying the original site of intrathecal
baclofen pump placement, 4 years after initial surgery. b Erect
abdominal radiograph showing the original intrathecal baclofen pump
device can be seen in the right lower quadrant of the abdomen with its
catheter tracking laterally and posteriorly towards the right flank and
onwards to the spinal column. c Lateral view abdominal radiograph
depicting the paucity of subcutaneous tissue overlying the original
pump site in the right lower quadrant of the abdomen
Fig. 3 a Revised pump site 6 months postoperatively. Significantly less
protrusion is seen with a subsequent decrease in tension on the overlying
skin. b Erect abdominal radiograph depicting the re-sited baclofen pump
in the posterior rectus fascial pouch. The catheter can be seen tracking
into the right flank and onwards towards the spinal column
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(1) situated deep to an area of relatively ‘clean’ skin, away from
creases; (2) contained within subcutaneous adipose tissue; (3)
away from a pressure point or bony prominence; (4) positioned
in such a way to allow uncomplicated refilling. These general
rules mirror those used in the alternative placement of other
medical devices such as cardiac pacemakers and implantable
external defibrillators. We advise that in cases of pump site skin
complication, the surgical strategy should be personalised, tak-
ing into account each patient’s anatomy and social requirement.
These two cases illustrate the circumstances that can threat-
en the sustainability of an existing intrathecal pump place-
ment. These cases, and the clinical decision-making surround-
ing their resolution, represent a logical starting point for the
holistic management of patients with similar circumstances
that may preclude traditional siting of an intrathecal pump.
Compliance with ethical standards
Funding No funding was received for this research.
Conflicts of interest None.
Ethical approval All procedures performed in studies involving human
participantswere in accordancewith the ethical standards of the institutional
and/or national research committee and with the 1964 Helsinki declaration
and its later amendments or comparable ethical standards.
Informed consent Informed consent was obtained from all individual
participants included in the study. Additional informed consent was ob-
tained from all individual participants for whom identifying information
is included in this article.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Bar-On L, Molenaers G, Aertbeliën E, Van Campenhout A,
Feys H, Nuttin B, Desloovere K (2015) Spasticity and its
contribution to hypertonia in cerebral palsy. Biomed Res Int
2015:317047
2. Nair KPS, Marsden J (2014) The management of spasticity in
adults. BMJ 349:g4737. doi:10.1136/bmj.g4737
3. Penn RD, Kroin JS (1984) Intrathecal baclofen alleviates spinal
cord spasticity. Lancet 1(8385):1078
4. Penn RD, Kroin JS (1987) Long-term intrathecal baclofen
infusion for treatment of spasticity. J Neurosurg 66(2):181–
185
5. McIntyre A, Mays R, Mehta S, Janzen S, Townson A, Hsieh J,
Wolfe D, Teasell R (2014) Examining the effectiveness of in-
trathecal baclofen on spasticity in individuals with chronic spi-
nal cord injury: a systematic review. J Spinal Cord Med 37(1):
11–18
6. Butler C, Campbell S, Adams R et al (2000) Evidence of the effects
of intrathecal baclofen for spastic and dystonic cerebral palsy. Dev
Med Child Neurol 42(9):634–645
7. Stetkarova I, Yablon SA, Kofler M, Stokic DS (2010)
Procedure- and device-related complications of intrathecal
baclofen administration for management of adult muscle
hypertonia: a review. Neurorehabil Neural Repair 24(7):
609–619
8. De Lissovoy G, Matza LS, Green H, Werner M, Edgar T (2007)
Cost-effectiveness of intrathecal baclofen therapy for the treatment
of severe spasticity associated with cerebral palsy. J Child Neurol
22(1):49–59
9. National Institute for Health and Clinical Excellence (2012)
Spasticity in children and young people with nonprogressive brain
disorders http://www.ncbi.nlm.nih.gov/books/NBK116583/.
Accessed 26 Oct 2015
10. Ammar A, Ughratdar I, Sivakumar G, Vloeberghs MH (2012)
Intrathecal baclofen therapy—how we do it. J Neurosurg Pediatr
10(5):439–444
11. Grabb P, Pittman A (1998) Subfascial placement of bac-
lofen pumps. Presented at the Annual Meeting of the
Jo in t Sec t ion of Ped ia t r i c Neuro log ica l Su rge ry,
Indianapolis
170 Acta Neurochir (2016) 158:167–170
